Outlook: Industry eyes potential new Rx business
This year, chain drug retailers will be busy preparing for what’s coming up next year.
Latest
Standley guides impressive turnaround at Rite Aid
No one has been more closely involved in the revitalization of Rite Aid Corp. than John Standley. John Standley Arriving at the company in December 1999 as part of an executive team called in after previous management pushed the drug chain to the verge of bankruptcy, Standley, who is now chairman,
SymphonyIRI Group rebrands as IRI
SymphonyIRI Group Inc. is returning to its founding name of Information Resources Inc. and rebranding as IRI.
Promo gives consumers chance to star in Dr. Pepper ads
Dr. Pepper Snapple Group has announced "Be the Next /1," a national consumer contest that offers fans the chance to star in upcoming national television commercials and digital advertising for the Dr. Pepper soft drink brand.
Lay’s Wavy gets new flavor, new look
Frito-Lay North America has extended its Lay’s Wavy potato chip line with the introduction of Lay’s Wavy Garlic & Sea Salt. The PepsiCo snack subsidiary said the new Lay’s Wavy Roasted Garlic & Sea Salt potato chips will be available in stores nationwide this month in a 9.5-ounce bag for a suggested
Bartell Drugs’ store base gets bigger, better
Bartell Drugs aims to open a pair of new locations this year as it continues efforts to enhance the shopping experience at its Seattle-area stores. Chairman and chief executive officer George Bartell said that in 2013 the drug chain plans to open store No.
Taro cleared to market Topicort spray
Taro Pharmaceutical Industries Ltd. has received approval from the Food and Drug Administration for Topicort Topical Spray 0.25%. The company said Friday that the Topicort (desoximetasone) spray, a corticosteroid, is indicated for the treatment of plaque psoriasis in patients age 18 and older.
Warner Chilcott receives FDA approval for Doryx tablets
Warner Chilcott has been cleared by the Food and Drug Administration to market 200-mg strength of Doryx delayed-release tablets. The Ireland-based pharmaceutical company said Friday that it expects the commercial launch of the Doryx tablets to take place in July.
NABP pursues .pharmacy domain for online Rx
The National Association of Boards of Pharmacy (NABP) envisions a safer online environment for buying medications with its proposed .pharmacy domain suffix. NABP said Monday that it expects the results of the Internet Corporation for Assigned Names and Numbers (ICANN) review process for the .
Navarro’s 33rd store makes its debut
Navarro Discount Pharmacy has opened its 33rd store, located on NW 7th Street in Miami. The NW 7th Street store in Miami offers a bigger selection of dairy products and other consumables.
PuraMed eyes bigger retail presence for LipiGesic M
PuraMed BioScience Inc. plans to ramp up the retail sales efforts for its LipiGesic M homeopathic migraine headache remedy by targeting another 21,000 retail outlets.
CVS/pharmacy aims to spur mobile app use via <br>free smartphone promo
CVS/pharmacy is spreading the word of its mobile application’s benefits via a new online promotion that offers up to 1 million free smartphones to consumers.
Consumer Reports: Discounters top drug stores on OTC prices
The leading discount chains are edging out the leading drug store chains when it comes to pricing on over-the-counter medicines, according to Consumer Reports.
Allegra expands into topical anti-itch products
Chattem Inc. has extended its Allegra allergy brand with a pair of topical anti-itch creams.
CVS Caremark helps PBM clients save by driving generics use
An analysis by CVS Caremark Corp. shows that the company reined in its pharmacy benefit management clients’ costs for medications, in part, through an industry-leading dispensing rate for generic drugs.
It’s a profitable fiscal year for Rite Aid Corp.
Adding fuel to its turnaround, Rite Aid Corp. closed out fiscal 2013 with a profit — its first in six years — and in the fourth quarter posted its second consecutive quarter of net income. The earnings for the fourth quarter and full year easily beat Wall Street’s consensus forecast and